Welichem Biotech Inc.

316-4475 Wayburne Drive
V5G 3L1 Burnaby
Canada

Contact

About Welichem Biotech

Welichem Biotech Inc. is engaged in the discovery and development of novel small molecule therapeutics. Using its Symbiochem technology platform, the Company has developed a robust pipeline of patent-protected compounds that target autoimmune/inflammatory diseases and cancers.

News about Welichem Biotech

15-Dec-2009 | research and development

Welichem Begins Patient Enrollment for Phase IIb Trial of WBI-1001 Creams in Patients with Atopic Dermatitis

Welichem announced that the Company has begun to enroll patients in a Phase IIb clinical trial with its lead candidate, WBI-1001. The Phase IIb clinical ...

Read news

13-Jan-2009 | people

Welichem Announces Appointment of New CFO

Welichem Biotech Inc. announced the appointment of Yue Zhao as Chief Financial Officer (CFO) of the Company, effective immediately. Ms. Yue brings in ...

Read news

27-Feb-2008 | research and development

Welichem Obtains Approval for Phase IIa Clinical Trial on Eczema

Welichem Biotech Inc. announced that Health Canada approved the Company's Clinical Trial Application (CTA) to begin a Phase IIa Clinical Trial of its anti- ...

Read news

21-Sep-2005 | research and development